Am­gen beefs up its late-stage pipeline with a $400M cash deal to go up against heavy­weight ri­vals in a PhI­II atopic der­mati­tis show­down

Three months af­ter Ky­owa Kirin claimed a hit for their mid-stage pro­gram test­ing the an­ti-OX40 an­ti­body KHK4083 for mod­er­ate to se­vere atopic der­mati­tis, Am­gen is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER